South Korea · Delayed Price · Currency is KRW Abpro Bio Statistics
Total Valuation
Abpro Bio has a market cap or net worth of KRW 39.03 billion. The enterprise value is 49.45 billion.
| Market Cap | 39.03B |
| Enterprise Value | 49.45B |
Important Dates
The next estimated earnings date is Thursday, May 14, 2026.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Abpro Bio has 28.47 million shares outstanding. The number of shares has increased by 0.03% in one year.
| Current Share Class | 28.47M |
| Shares Outstanding | 28.47M |
| Shares Change (YoY) | +0.03% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 3.21% |
| Owned by Institutions (%) | 0.31% |
| Float | 26.42M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.22 |
| PB Ratio | 0.72 |
| P/TBV Ratio | 0.93 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.01 |
| EV / Sales | 1.55 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -5.75 |
Financial Position
The company has a current ratio of 3.22, with a Debt / Equity ratio of 0.29.
| Current Ratio | 3.22 |
| Quick Ratio | 1.12 |
| Debt / Equity | 0.29 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.80 |
| Interest Coverage | -6.78 |
Financial Efficiency
Return on equity (ROE) is -60.38% and return on invested capital (ROIC) is -10.38%.
| Return on Equity (ROE) | -60.38% |
| Return on Assets (ROA) | -5.37% |
| Return on Invested Capital (ROIC) | -10.38% |
| Return on Capital Employed (ROCE) | -13.98% |
| Weighted Average Cost of Capital (WACC) | 4.94% |
| Revenue Per Employee | 725.52M |
| Profits Per Employee | -1.11B |
| Employee Count | 44 |
| Asset Turnover | 0.30 |
| Inventory Turnover | 2.10 |
Taxes
| Income Tax | -416.39M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -55.05% in the last 52 weeks. The beta is -0.02, so Abpro Bio's price volatility has been lower than the market average.
| Beta (5Y) | -0.02 |
| 52-Week Price Change | -55.05% |
| 50-Day Moving Average | 1,845.78 |
| 200-Day Moving Average | 2,395.40 |
| Relative Strength Index (RSI) | 39.40 |
| Average Volume (20 Days) | 3,373,736 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Abpro Bio had revenue of KRW 31.92 billion and -48.92 billion in losses. Loss per share was -171.84.
| Revenue | 31.92B |
| Gross Profit | 3.51B |
| Operating Income | -9.28B |
| Pretax Income | -49.34B |
| Net Income | -48.92B |
| EBITDA | -7.58B |
| EBIT | -9.28B |
| Loss Per Share | -171.84 |
Balance Sheet
The company has 5.08 billion in cash and 15.50 billion in debt, with a net cash position of -10.42 billion or -366.10 per share.
| Cash & Cash Equivalents | 5.08B |
| Total Debt | 15.50B |
| Net Cash | -10.42B |
| Net Cash Per Share | -366.10 |
| Equity (Book Value) | 54.03B |
| Book Value Per Share | 51.29 |
| Working Capital | 18.60B |
Cash Flow
In the last 12 months, operating cash flow was -6.69 billion and capital expenditures -1.92 billion, giving a free cash flow of -8.60 billion.
| Operating Cash Flow | -6.69B |
| Capital Expenditures | -1.92B |
| Depreciation & Amortization | 1.66B |
| Net Borrowing | -5.70M |
| Free Cash Flow | -8.60B |
| FCF Per Share | -302.12 |
Margins
Gross margin is 11.00%, with operating and profit margins of -29.06% and -153.24%.
| Gross Margin | 11.00% |
| Operating Margin | -29.06% |
| Pretax Margin | -154.55% |
| Profit Margin | -153.24% |
| EBITDA Margin | -23.76% |
| EBIT Margin | -29.06% |
| FCF Margin | n/a |
Dividends & Yields
Abpro Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.03% |
| Shareholder Yield | -0.03% |
| Earnings Yield | -125.34% |
| FCF Yield | -22.04% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on February 20, 2026. It was a reverse split with a ratio of 0.1.
| Last Split Date | Feb 20, 2026 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
Abpro Bio has an Altman Z-Score of -0.62 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.62 |
| Piotroski F-Score | 4 |